NCT05896839
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer treatment 1 / 2 recruiting NCT06500455
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain No drug interventions treatment 3 recruiting NCT01989585
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma treatment 1 / 2 active_not_recruiting NCT04314401
National Cancer Institute "Cancer Moonshot Biobank" No drug interventions Not Available Not Available recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT04557956
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment treatment 1 / 2 recruiting NCT04697576
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma treatment 1 recruiting NCT05764395
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors treatment 2 suspended NCT03873818
Low Dose Ipilimumab with Pembrolizumab in Treating Patients with Melanoma That Has Spread to the Brain treatment 2 active_not_recruiting NCT05098210
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer treatment 1 recruiting NCT04940299
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma treatment 2 active_not_recruiting NCT05388877
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma treatment 1 recruiting NCT05967533
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors No drug interventions treatment 1 recruiting NCT06151847
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma treatment 2 recruiting NCT05026983
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases treatment 2 recruiting NCT03816332
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers treatment 1 active_not_recruiting NCT02298959
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer treatment 1 active_not_recruiting NCT04462406
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial treatment 2 recruiting NCT05341349
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases treatment 1 recruiting NCT04511013
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases treatment 2 recruiting NCT03698019
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma treatment 2 active_not_recruiting NCT05136196
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study treatment 2 suspended NCT02650986
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 treatment 1 / 2 active_not_recruiting NCT01738139
Ipilimumab and Imatinib Mesylate in Advanced Cancer treatment 1 completed NCT04516122
Bone Loss in Melanoma Survivors Receiving Immunotherapy No drug interventions Not Available Not Available active_not_recruiting NCT04375527
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma treatment 2 recruiting NCT01644591
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases No drug interventions treatment 2 active_not_recruiting NCT03727789
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma No drug interventions treatment 1 terminated NCT04007744
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors treatment 1 recruiting NCT04902040
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies treatment 1 / 2 recruiting NCT05039801
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors treatment 1 recruiting NCT04789668
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases treatment 1 / 2 completed NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT02224781
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma treatment 3 active_not_recruiting NCT02419495
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT05588453
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain treatment 1 / 2 recruiting NCT02506153
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery treatment 3 active_not_recruiting NCT02020707
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers treatment 1 completed NCT03025256
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease treatment 1 active_not_recruiting NCT06265285
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program health_services_research 2 recruiting NCT03175432
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases treatment 2 active_not_recruiting NCT06391099
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer No drug interventions supportive_care Not Available not_yet_recruiting NCT04527549
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma treatment 2 terminated NCT06075524
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types No drug interventions Not Available Not Available recruiting NCT04967196
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma treatment 1 active_not_recruiting NCT03819296
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer treatment 1 / 2 recruiting NCT04941430
7T MRI Scan for the Early Detection of Melanoma Brain Metastases No drug interventions diagnostic Not Available recruiting NCT02595866
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer treatment 1 completed NCT05102773
The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients No drug interventions Not Available Not Available completed NCT03033576
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma treatment 2 active_not_recruiting NCT04067960
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer No drug interventions screening 0 completed NCT04645680
Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study No drug interventions supportive_care 2 active_not_recruiting NCT05717140
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung treatment 1 not_yet_recruiting NCT04752267
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases diagnostic 0 completed NCT03865212
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma treatment 1 active_not_recruiting NCT05907512
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma prevention 2 recruiting